| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:22446829 | IVTH | 0.001 - 1 mg/L | 1 mg/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.001 - 1 mg/L | 1 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.001 - 1 mg/L | 1 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:26183808 | IVR | 300 mg/kg | 300 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 300 mg/kg | 300 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 300 mg/kg | 300 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| PMID:26979758 | IVTH | 0.001 M | 0.001 M | Altered estrogen levels | Reproductive endocrine-mediated perturbations |
| PMID:28430429 | IVTH | 0.00000001 - 0.00001 M | 0.000002 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:29466770 | IVR | 0.002 mg/day | 0.002 mg/day | Affects lipid metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.2 mg/day | 0.2 mg/day | Affects gluconeogenesis | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/day | 0.2 mg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/day | 0.2 mg/day | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:32567707 | IVR | 25 mg/kg | 25 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:34600017 | IVTH | 0.00002 - 0.0002 M | 0.00002 - 0.0002 M | Affects lipid metabolism | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00002 - 0.0002 M | 0.00002 - 0.0002 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| PMID:35135005 | IVTH | 0.000005 - 0.00005 M | 0.000005 - 0.00005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:35563431 | IVTH | 0.0000000001 - 0.000001 M | 0.0000000001 - 0.000001 M | Elevated insulin levels | Metabolic endocrine-mediated perturbations |
| PMID:37522340 | IVTH | 0.000001 M | 0.000001 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.000005 M | 0.000001 - 0.000005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 - 0.000005 M | 0.000001 - 0.000005 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:38048832 | IVTH | 0.00003 M | 0.00003 M | Altered lipid composition in adipocytes | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00003 M | 0.00003 M | Altered adipocyte morphology | Metabolic endocrine-mediated perturbations | |
| PMID:38450882 | IVTH | 0.000011 - 0.000033 M | 0.000011 - 0.000033 M | Increased cholesterol levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000011 - 0.000033 M | 0.000011 - 0.000033 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000011 - 0.000033 M | 0.000011 - 0.000033 M | Altered adipogenesis | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000033 M | 0.000033 M | Increased glucocorticoid levels | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVTH | 0.000033 M | 0.000033 M | Increased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000033 M | 0.000033 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000033 M | 0.000033 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000011 - 0.000033 M | 0.000011 - 0.000033 M | Increased HDL levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000011 - 0.000033 M | 0.000011 - 0.000033 M | Increased LDL levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.